| Budget Amount *help |
¥55,640,000 (Direct Cost: ¥42,800,000、Indirect Cost: ¥12,840,000)
Fiscal Year 2014: ¥11,570,000 (Direct Cost: ¥8,900,000、Indirect Cost: ¥2,670,000)
Fiscal Year 2013: ¥12,220,000 (Direct Cost: ¥9,400,000、Indirect Cost: ¥2,820,000)
Fiscal Year 2012: ¥12,740,000 (Direct Cost: ¥9,800,000、Indirect Cost: ¥2,940,000)
Fiscal Year 2011: ¥12,610,000 (Direct Cost: ¥9,700,000、Indirect Cost: ¥2,910,000)
Fiscal Year 2010: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Outline of Final Research Achievements |
Natural product biosynthesis has long been affording interesting and important organic compounds. The biosynthetic systems are apparently a sort of designer assembly line. Recent advances in genetics and molecular biology as well as chemical technology will be beneficial in understanding the precise nature of the biosynthetic machinery and in engineering the machinery to produce natural and unnatural products. In this project, our own approach to this field, particularly focusing on the mechanistic enzymology as well as genetic analysis of biosynthesis of several macrolactam (vicenistatin, incednine, cremimycin, and hitachimycin) and aminoglycoside antibiotics (neomycin, butirosin, and kanamycin), was performed.
|
